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Background: Rhabdoid colorectal tumor (RCT) is a rare, highly aggressive neoplasm recurrent in elderly patients,
commonly at the caecum. The molecular mechanisms underlying RCT pathogenesis remain poorly elucidated. The
differential diagnosis is with the malignant rhabdoid tumors of infancy characterized by genetic inactivation of
SMARCB1 (INI1) or deletions of chromosome 22q12 locus.
Materials and methods: To shed light on RCT pathogenesis, we investigated genetic and epigenetic alterations in
two cases of pure and composite RCT and compared them with the profiles of matched adenomas and normal
mucosa. Immunohistochemical analysis, FISH, methylation specific PCR and DNA sequencing analysis were
performed on paraffin-embedded tissues.
Results: Loss of epithelial markers, (CK20, CDX2 and E-cadherin) and intense vimentin expression was observed in
RCTs but neither in the normal mucosa or adenomas. INI1 expression was detected in normal mucosa, adenomas
and retained in pure RCT, while it was undetected in composite RCT. Rearrangement of the 22q12 locus was found
only in pure RCT. The APC/β-catenin pathway was not altered, while MLH1 immunostaining was negative in RCTs
and positive in adenomas and normal mucosa. These expression profiles were associated with V600E BRAF
mutation, a progressive accumulation of promoter methylation at specific CIMP loci and additional genes from the
normal mucosa to tubular adenoma and RCT.
Conclusions: Right-sided RCT could be characterized by epigenetic events and molecular features likely similar to
those occurring in the serrated pathway and associated with epithelial-mesenchymal transition. These extremely
rare tumors may benefit from the use of new biological molecules specific for colorectal carcinoma.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1641385210804556
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Rhabdoid colorectal tumor (RCT) is a rare lesion mainly
localized to the proximal colon in patients with a mean
age at diagnosis around 70 years. Only 7 cases of RCT
have been reported in the literature to the best of our
knowledge [1-3]. This tumor shows an aggressive behav-
iour and fatal outcome displaying an overall survival* Correspondence: colantuoni@unisannio.it
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reproduction in any medium, provided the orshorter than 12 months [1-3]. The diagnostic hallmark
of this neoplasm is the presence of rhabdoid cells char-
acterized by an eccentrically located and large nucleus,
prominent nucleoli and cytosolic aggregates of inter-
mediate filaments [1-3]. The amount and distribution of
the rhabdoid component in neoplasms is highly variable
ranging from “composite,” in which the rhabdoid ele-
ments are associated with adenocarcinoma, to the “pure”
rhabdoid carcinoma without an evident epithelial com-
ponent [1,2]. The main differential diagnosis is with the
malignant rhabdoid tumors (MRT), a neoplasm more
common in childhood and characterized by genetical Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of the SWI/SNF chromatin remodelling complex or de-
letions of chromosome 22q [4-6]. The events involved in
RCT pathogenesis, however, remain poorly elucidated
[1-3]. In order to shed light on the molecular mecha-
nisms underlying the stepwise rhabdoid carcinogenesis,
we investigated the genetic and epigenetic alterations in-
volved in two RCTs and compared with matched aden-
omas and normal mucosa.
Materials and methods
Paraffin-embedded specimens of the neoplastic glandu-
lar and rhabdoid components of a pure and composite
RCT were studied and compared to the matched normal
mucosa and adenomas.
Case I
A large and irregular carcinoma, measuring 10 × 10 cm
and graded as T3N1M0, was diagnosed at the right colon
and surgically removed in a 71-year-old woman at the
Rummo Hospital, Benevento, Italy. Histologically, the
tumor showed rhabdoid features without an apparent
glandular component (pure RCT). Immunophenotipic,
morphological and molecular findings supported its colo-
rectal origin [2]. The patient was affected by essential
hypertension and declared that her mother died ofba EO EO
e Vim f INI1
Figure 1 Immunohistochemical markers of colon carcinoma with rhab
(a) Hematoxylin&Eosin staining of the rhabdoid component in the compos
larger dysplastic adenoma with a cancerized component contiguous to the
staining in the large dysplastic adenoma adjacent to the composite RCT. (e
rhabdoid cells of pure RCT (case I) (f) Intense INI1 nuclear immunostaining
component of composite RCT showing appropriate staining of intratumora
staining marks the transition from adenoma to carcinoma in larger dysplascolorectal carcinoma (CRC). After surgery, she underwent
adjuvant chemotherapy (Folfox for 3 months). Despite a
target therapy as second line treatment (4 cycles of
bevacizumab followed by 2 cycles of cetuximab), tumor
dissemination to the peritoneum and liver occurred and
the patient died only 8 months from surgery [2].
Case II
The patient, a 73-year-old woman, was CRC diagnosed at
the Legnago Hospital (Verona, Italy). The lesion, 10 × 8
cm in size, localized to the right colon, was graded as
T4N1M0 [1]. Histologically, the tumor was heterogeneous,
consisting of an adenocarcinoma associated with promin-
ent rhabdoid features (composite RCT) (Figure 1a). Six
tubular adenomas (TA) close to the carcinoma, were also
present, among which the largest in size showed an
infiltranting area of neoplastic cells (cancerized tubular ad-
enoma, CTA) (Figure 1b, c). The area of rhabdoid dediffer-
entiation was approximately 40% of the entire tumor
mass. The area of interest for each histological section was
isolated and analyzed on the basis of its morphology.
Patient’s anamnestic history revealed an essential hyper-
tension and a meningioma at 31 years of age that was
surgically removed; Only a sibling, among the proband’s
first-degree relatives, was affected by CRC under 60 years
of age; no family history nor other malignancies werec EO
g INI1 p53h
d -catenin
doid features, adjacent adenomas and normal mucosa.
ite RCT (case II) (b). Low-power view of tubular adenomas and (c) a
main tumor mass of the composite RCT. (d) Membrane β-catenin
) Intense and diffuse vimentin immunohistochemical staining in
in rhabdoid cells of case I (g) Loss of INI1 staining in the rhabdoid
l lymphocytes serving as internal control. (h) A strong nuclear p53
tic polyps. Magnification (×200 or ×400).
Table 1 Comparison of immunohistochemical markers
between adjacent normal mucosa, tubular adenomas and
RCT
Table 1 Pure RCT (case I) Composite RCT (case II)
Markers NM1 RC NM2 TA CTA GC RC
CK20 +++ neg. +++ +++ +++ + neg.
CK7 neg neg. neg. neg. neg. neg. neg.
CDX2 +++ neg. +++ +++ +++ + neg.
E-cadherin ++ neg. ++ ++ ++ + neg.
β-catenina (a) + + + + + ++ neg.
APC (c-ter) ++ ++ ++ ++ +++ ++ ++
p53 neg. ++ neg. + +++ ++ +
Vimentin neg. +++ neg. neg neg. ++ +++
CK18 + + + ++ ++ + ++
CK19 ++ ++ ++ ++ ++ + ++
CK-Pan +++ ++ +++ +++ +++ +++ +++
HDAC1 + +++ + + ++ ++ +++
HDAC2 + +++ + + ++ ++ +++
HDAC3 + +++ + + ++ ++ +++
VEGFR1 neg. neg. neg. + + neg. neg.
VEGFR2 neg. +++ neg. neg. neg. ++ ++
MLH1 +++ neg. +++ ++ ++ neg. neg.
MSH2 +++ + ++ ++ ++ ++ ++
TS + + + ++ ++ + +
INI1 + +++ + + ++ + neg.
(+++): widespread occurrence, intense expression; (++): Varying distribution,
moderate expression; (+): Limited occurrence, low expression; (−) no
occurrence or negative. aβ-catenin nuclear localization; Abbreviations:
Cytokeratin, CK; pure rhabdoid colorectal tumor, case I (RCTI); glandular (GC)
and rhabdoid (RC) components of composite rhabdoid colorectal tumor, case
II (RCTII); adjacent tubular adenomas (TA), cancerized and larger tubular
adenoma (CTA) or normal mucosa (NM2) of case II. Case I, a pure RCT, is
compared to the adjacent distant non-neoplastic mucosa (NM1); histone
deacetylase, HDAC; vascular endothelial growth factor receptors, VEGFR;
thymidylate synthase, TS.
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(capecitabin and oxaliplatin) with no clinical benefits.
She died for metastatic progression of the disease to the
liver only 6 months after surgery [1].
Immunohistochemical, methylation and DNA sequencing
analysis
Four μm tick sections were used for routine stainings, im-
munohistochemistry and DNA extraction. Immunohisto-
chemical analysis was performed as previously described
[1,2] by using the following antibodies: VEGFR1 (sc-65442)
and VEGFR2 (sc-101560); thymidylate synthase (TS)
(sc-33679); APC (sc-896); (Santa Cruz Biotechnology, Santa
Cruz, Ca, USA); HDACI (ab19845), HDACII (ab61216),
HDACIII (ab-32117) (Abcam, Cambridge, UK); INI1
(25/BAF47) (DAKO Cytomation, Glostrup, Denmark). E-
cadherin, 610405 and β-catenin (610153) (Transduction
Laboratories, Lexington, KY, USA); cytokeratin 7 (CK7)
clone-RN7; CK18-clone DC-10; CK19-clone b170; CK20-
clone Ks 20.8; CK-Pan-clone AE1/AE3; epidermal growth
factor receptor (EGFR)-clone EGFR.113; vimentin-clone
VIM 3B4; desminclone DE-R-11; (Novocastra Laborator-
ies, Newcastle, UK). p53 clone-Bp53-11; anti-MLH1 clone-
M1; anti-MSH2 clone-G219-1129; (Ventana Medical
Systems, Tucson, AZ, USA). Genomic DNA isolation
and sodium bisulphite modification were carried out as
reported [2]. The converted DNA was subjected to
methylation specific PCR (MSP) using unmethylated and
methylated controls in each reaction. The methylation
levels (ratios of methylated to unmethylated and methyl-
ated DNA (M/U+M × 100) were determined from the
relative band intensities and scored as follow: Negative
(0-20% methylation); Low (>20-60%); High (>60%) [7].
Primers for promoter methylation analysis were designed
and validated as reported [8]. A detailed description of
the primer sets and MSP conditions has already been
reported or will be provided upon request [2]. EWS re-
arrangement at the chromosome locus 22q12, MYH,
BRAF and KRAS mutations were analyzed as previously
reported [2,9].
Results
Immunohistochemical profile and predictive markers in RCTs
To evaluate whether common pathogenetic mechanisms
underlie the development of RCT, we analyzed markers
involved in colonic differentiation, epigenetic gene silen-
cing, and predictors of drug resistance. Cytokeratin 20
(CK20), E-cadherin, CDX2 and β-catenin immunoreactiv-
ity were completely absent in the rhabdoid component
and focally positive only in the glandular component
(Figure 1d, and Table 1). Vimentin immunostaining was
intense and diffuse in both cases, either in the rhabdoid
and glandular neoplastic cells (Figure 1e, and Table 1).
The matched normal mucosa and all adenomas tested, incontrast, were negative for vimentin and positive for epi-
thelial markers (Table 1). Epigenetic and drug sensitivity
markers, such as histone deacetylase isoforms (HDACs I-
III) or vascular endothelial growth factor receptors 2
(VEGFR-2), were strongly or moderately positive in both
cases, whereas thymidylate synthase (TS) and vascular
endothelial growth factor receptors 1 (VEGFR-I) were fo-
cally immunoreactive (Table 1). INI1 immunostaining was
weakly positive in normal mucosa, all adenomas and
strongly positive in the pure RCT; conversely, it was fo-
cally positive in the glandular and totally negative in the
rhabdoid component of the composite RCT (Figure 1f, g
and Table 1).
BRAF mutations and MSI are the predominant genetic
alterations in RCT pathogenesis
RCTs were characterized by the presence of the V600E
BRAF mutation both in the rhabdoid and glandular com-
ponent and by high microsatellite instability (MSI-H) due
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tigate the genetic events involved in RCT development,
we analyzed by FISH deletions or rearrangements at the
EWS locus at 22q12 as they are detected in several MRTs
[10]. The 22q12 locus was rearranged only in the pure
RCT, but not in the composite tumor (Figure 2A). Subse-
quently, we compared the BRAF/KRAS mutational and
the microsatellite stability status of the RCTs with the
matched tubular adenomas (TAs) and normal mucosa. No
BRAF mutations were found in all analyzed adenomas and
normal adjacent mucosa (Figure 2A). The G12D KRAS
mutation, in contrast, was found only in the larger dys-
plastic tubular adenoma with infiltrating carcinoma
(CTA); only in this latter component an intense nuclear
p53 expression was present, marking the transition from
adenoma to carcinoma (Figure 1h, and Table 1). A negative
immunostaining for MLH1 and a variable positivity for
MSH2 were found in both RCTs (Table 1). MLH1 and
MSH2 expression was positive in normal mucosa and in
all adenomas tested, suggesting that high MSI wasFigure 2 Genetic and epigenetic survey of a composite and pure rhab
pure RCT (case I) and composite (case II) RTC. Tumor tissue of case II is cha
molecular alterations are compared to the adjacent tubular adenomas (TA)
(NM2). Case I, a pure RCT, is compared to the adjacent distant non-neoplas
RUNX3 are reported. (B) Representative sequencing analysis of MYH using D
codons 165, 382 and 391, respectively. Note: Break-apart FISH assay was us
Abbreviations: Nd: Not determined; Nr: Normal or intact locus; Re: Rearran
MSI:microsatellite instability.confined solely to RCTs (Figure 2A). The staining for APC
(cytosolic), β-catenin (membrane) and CDX2 showed a
normal pattern in all TAs tested and in normal mucosa
(Table 1). These unexpected results prompted us to investi-
gate whether other genetic alterations might be responsible
for these lesions. To this goal we checked for MYH muta-
tions at the most frequent hot spots, Y179C (exon7) and
G396D and P391L (exon12) [11]. No mutations were
found in RCTs and in normal mucosa (Figures 2A and 2B).
Widespread CpG island promoter methylation is a feature
of the rhabdoid trait
The presence of a CpG island methylation profile in a
tumor defines the CpG island methylator phenotype
(CIMP), an epigenetic alteration considered as a novel
genome instability event in CRC pathogenesis [12-14].
We assessed the DNA methylation levels of six CIMP
markers, MLH1, RUNX3, NEUROG1, IGF2, SOCS1 and
CDKN2A in the normal mucosa, TA and RCT. Only in
the RCTs, high levels of DNA methylation (from 80 todoid tumor. (A). Genetic, cytogenetic and epigenetic analysis of the
racterized by a glandular (GC) and rhabdoid (RC) component whose
, the cancerized and larger tubular adenoma (CTA) or normal mucosa
tic mucosa (NM1). Six CIMP loci MLH1, CDKN2A, IGF2, SOX2, NEUROG1,
NA isolated from the rhabdoid tumor tissue shows no mutations at
ed to analyze 22q12 (EWS) rearrangement as reported in Ref 2.
ged locus; CIMP: CpG island methylator phenotype;
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and 3B). Methylation at SOCS1 and CDH1 promoter re-
gions was significantly higher in the rhabdoid than in the
glandular component of the composite RCT (Figure 3A).
CIMP loci methylation was only 30% in CTA, 16% in TAFigure 3 Genome widespread CpG island promoter methylation is a m
promoter methylation analysis carried out on 14 genes; six are the canonic
RUNX3); the others are either involved in cell cycle control as CDKN1B and
as XPD, XPA. The differential promoter methylation level in rhabdoid colore
specific PCR analysis at three CIMP loci (MLH1, RUNX3, CDKN2A) and CTNNB
methylated (M) control, respectively. (C) Progressive accumulation of prom
adenomas and finally to composite RCT. (D) The schematic drawing illustra
originates through an alternative pathway resembling the serrated pathwa
rhabdoid colorectal tumor case II (RCTII). NM: normal mucosa; TA: tubular aand relatively low or absent in the normal mucosa
(Figure 3C). The methylation survey was extended to
other genes not included in the CIMP panel, as their epi-
genetic changes in RCT pathogenesis have not been inves-
tigated so far. RARβ, CTNNB1, CDKN1B, CDKN1C, XPD,olecular feature of RCT pathogenesis. (A) The table reports the
al, representative CIMP loci (MLH1, CDKN2A, IGF2, SOX2, NEUROG1,
CDKN1C; or in cell-cell adhesion as CDH1 and CTNNB1 or in DNA repair
ctal and adjacent lesions is shown. (B) Representative methylation
1 (β-catenin) in case I; (PC) indicates positive unmethylated (U) or
oter methylation at six specific CIMP loci from normal mucosa, tubular
tes the possible CRC pathogenetic mechanisms; rhabdoid CRC
y. Abbreviations: glandular (GC) and rhabdoid (RC) component of
denoma; CTA: cancerized tubular adenoma.
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ential methylation levels during RCT progression; only
XPD promoter methylation seemed to mark RCT specific-
ally (Figure 3A).
Discussion
Over the past twenty years, only seven cases of colorectal
tumors with a rhabdoid phenotype have been reported
[1-3]. These tumors are generally found in elderly patients
at the proximal colon and show an aggressive behaviour
characterized by an overall survival time shorter than 12
months [1,2]. The main differential diagnosis is with the
malignant rhabdoid tumors (MRTs), a neoplasm more
common in childhood characterized by genetic inactiva-
tion of SMARCB1 (SNF5, INI-1), a component of the
SWI/SNF chromatin remodelling complex or deletions at
chromosome 22q [4-6]. Loss of epithelial markers, such as
CK20, CDX2 and E-cadherin was observed in RCTs but
neither in the matched normal mucosa nor adenomas. Al-
though loss of CK20 and CDX2 is commonly observed in
right-sided colorectal carcinoma [15,16] with high tumor
grades and high microsatellite instability, the progressive
increase of vimentin immunoreactivity may indicate that
the sarcomatous dedifferentiation occurs in late stages of
rhabdoid carcinogenesis and could be a crucial event in
the transition from adenocarcinoma to RCT [1-3]. Usually,
RCTs express high levels of EGFR [1,2], a finding that is
recurrent also in other subgroups of highly aggressive
CRCs. These results suggest that a combined assessment
of CDX2, Vimentin and EGFR may be of clinical value to
make a differential diagnosis, to predict a poor patients’
outcome or to choose the best fit biological therapy
[17,18]. INI1 loss-of-function mutations have been identi-
fied in pediatric MRTs, whereas their role in adult extra-
renal rhabdoid tumors is still elusive [5,6]. Although loss
of INI1 expression is a constant finding in MRT of soft tis-
sues, kidney or central nervous system (CNS), INI1 stain-
ing was positive in the normal mucosa, adenomas and
intensely in pure RCT, and negative in the composite
RCT. Loss of INI1 in MRT is mainly due to mutations
and/or deletions of the 22q11.2 locus; alternatively, it may
be due to epigenetic events. The 22q12 locus was normal
in composite RCT with lack of INI1 whereas it was
rearranged in pure RCT with an intense INI1 staining,
supporting the hypothesis of gene inactivation possibly by
epigenetic mechanisms. The EWS gene is located on
chromosome 22q12 and its translocation with members of
the ETS families is a recurrent alteration in Ewing sar-
coma, although other EWS rearrangements or deletions
have been identified in different pathologies including
composite rhabdoid tumors of the endometrium [10,19].
A rearrangement was detected in the pure RCT, the epi-
thelial origin of which has already been reported [2].
Although chromosome 22 alterations are common inMRTs, their role in CRC and RCT is still unknown and
further studies are required [19].
The APC/β-catenin pathway seems to be not affected
ruling out that RTC originates through the traditional ad-
enoma–carcinoma pathogenetic pathway underlying most
CRCs (Figure 3D). A KRAS mutation was found only in
the CTA, while nuclear p53 accumulation was observed
exclusively in its cancerized component. Interestingly, no
mutations were found in the base excision repair gene
MYH, whose mutations predispose to an hereditary colo-
rectal cancer syndrome defined “MYH associated polyp-
osis” (MAP) characterized by multiple adenomas mainly
at the right colon [9,11]. While our data do not exclude
that RCT may bear causative mutations in other yet un-
known loci, they, however, confirm that MYH is not re-
sponsible either for the precursor or tumor lesions.
Microsatellite instability (MSI) due to deficiency of the
mismatch repair system has been described in about 15-
20% of sporadic CRCs, characterized by poor differenti-
ation, infiltrating lymphocytes, a mucinous phenotype and
a more proximal localization than inherited HNPCCs
[12-14]. MLH1 epigenetic silencing is the most frequent
event responsible for MSI and is associated with BRAF
mutations in the serrated pathway [13,20]. In our RTCs,
MLH1 staining was negative, while it was nuclear and
diffuse in all adenomas and adjacent normal mucosa. Re-
markably, this expression profile was associated with the
presence of BRAF mutations in the same tissues, strongly
supporting our hypothesis that RTC does not arise through
the traditional adenoma-carcinoma sequence (Figure 3D).
Rather, it suggests that RCT may evolve through the ser-
rated pathway [14]. At the best of our knowledge, these
genetic alterations have not been reported in MRT
suggesting a colonic origin of RCT.
MLH1 silencing is usually associated with hypermethylation
at the CpG islands in multiple gene promoters [21]. Inter-
estingly, we found a progressive accumulation of promoter
methylation at specific CIMP loci and additional genes
from the normal mucosa to tubular adenoma, CTA and
RCT. A CpG island methylation threshold seems to be re-
quired for repression ofMLH1 and other important CIMP
loci in the composite RCT: a promoter methylation above
60% was, in fact, required for MLH1 down-regulation, as
reported [21,22]. At the right colon, a CIMP+ phenotype
and microsatellite instability (CIMP+/MSI+) may predis-
pose to RCT development, in agreement with recent stud-
ies reporting that CIMP+/MSI+ subtypes have a worse
clinical behaviour and prognosis than patients with CIMP-/
MSI+ [14].
Conclusions
Clinical and molecular features suggest that RCT may
be considered a distinct colonic entity and could benefit
from specific treatments with novel biological molecules.
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http://www.diagnosticpathology.org/content/8/1/31Right-sided RCT could be characterized by epigenetic
events similar to those occurring in the serrated pathway
with a marked epithelial-mesenchymal transition. Fur-
ther investigations involving more cases, albeit rare, are
mandatory to support this hypothesis.
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